Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 210

1.

A Digital Pathology-Based Shotgun-Proteomics Approach to Biomarker Discovery in Colorectal Cancer.

Zahnd S, Braga-Lagache S, Buchs N, Lugli A, Dawson H, Heller M, Zlobec I.

J Pathol Inform. 2019 Dec 12;10:40. doi: 10.4103/jpi.jpi_65_18. eCollection 2019.

2.

Correction to: Assessment of individual tumor buds using keratin immunohistochemistry: moderate interobserver agreement suggests a role for machine learning.

Bokhorst JM, Blank A, Lugli A, Zlobec I, Dawson H, Vieth M, Rijstenberg LL, Brockmoeller S, Urbanowicz M, Flejou JF, Kirsch R, Ciompi F, van der Laak JAWM, Nagtegaal ID.

Mod Pathol. 2020 Jan 3. doi: 10.1038/s41379-019-0450-2. [Epub ahead of print]

PMID:
31900432
3.

Assessment of individual tumor buds using keratin immunohistochemistry: moderate interobserver agreement suggests a role for machine learning.

Bokhorst JM, Blank A, Lugli A, Zlobec I, Dawson H, Vieth M, Rijstenberg LL, Brockmoeller S, Urbanowicz M, Flejou JF, Kirsch R, Ciompi F, van der Laak JAWM, Nagtegaal ID.

Mod Pathol. 2019 Dec 16. doi: 10.1038/s41379-019-0434-2. [Epub ahead of print] Erratum in: Mod Pathol. 2020 Jan 3;:.

PMID:
31844269
4.

Evaluation of Tumor Budding in Primary Colorectal Cancer and Corresponding Liver Metastases Based on H&E and Pancytokeratin Staining.

Blank A, Schenker C, Dawson H, Beldi G, Zlobec I, Lugli A.

Front Med (Lausanne). 2019 Oct 31;6:247. doi: 10.3389/fmed.2019.00247. eCollection 2019.

5.

Tumour Budding/T-cell infiltrates in Colorectal Cancer: Proposal of a Novel Combined Score.

Dawson H, Christe L, Eichmann M, Reinhard S, Zlobec I, Blank A, Lugli A.

Histopathology. 2019 Sep 27. doi: 10.1111/his.14006. [Epub ahead of print]

PMID:
31560788
6.

Cell Line Derived Xenograft Mouse Models Are a Suitable in vivo Model for Studying Tumor Budding in Colorectal Cancer.

Georges LMC, De Wever O, Galván JA, Dawson H, Lugli A, Demetter P, Zlobec I.

Front Med (Lausanne). 2019 Jun 27;6:139. doi: 10.3389/fmed.2019.00139. eCollection 2019.

7.

Co-expression of cytokeratin and vimentin in colorectal cancer highlights a subset of tumor buds and an atypical cancer-associated stroma.

Meyer SN, Galván JA, Zahnd S, Sokol L, Dawson H, Lugli A, Zlobec I.

Hum Pathol. 2019 May;87:18-27. doi: 10.1016/j.humpath.2019.02.002. Epub 2019 Feb 20.

PMID:
30794893
8.

Reply to: Interobserver variability in colorectal cancer and the 2016 ITBCC consensus.

Dawson H, Kirsch R, Lugli A; participants of the International Tumor Budding Consensus Conference 2016 (1).

Mod Pathol. 2019 Jan;32(1):161-162. doi: 10.1038/s41379-018-0104-9. Epub 2018 Dec 19. No abstract available.

9.

Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10.

Kienle DL, Dietrich D, Ribi K, Wicki A, Quagliata L, Winterhalder RC, Koeberle D, Horber D, Bastian S, Kueng M, Saletti P, Helbling D, Baertschi D, Lugli A, Bernhard J, Andrieu C, von Moos R.

J Geriatr Oncol. 2019 Mar;10(2):304-310. doi: 10.1016/j.jgo.2018.11.011. Epub 2018 Dec 14.

PMID:
30559073
10.

Validation of the International Tumor Budding Consensus Conference 2016 recommendations on tumor budding in stage I-IV colorectal cancer.

Dawson H, Galuppini F, Träger P, Berger MD, Studer P, Brügger L, Zlobec I, Inderbitzin D, Lugli A.

Hum Pathol. 2019 Mar;85:145-151. doi: 10.1016/j.humpath.2018.10.023. Epub 2018 Nov 11.

11.

Implementation of modern tools in autopsy practice-the way towards contemporary postmortal diagnostics.

Langer R, Tröhler A, Schnüriger B, Trippel M, Blank A, Banz Y, Candinas D, Perren A, Lugli A.

Virchows Arch. 2019 Feb;474(2):149-158. doi: 10.1007/s00428-018-2482-2. Epub 2018 Nov 13.

PMID:
30426205
12.

Stromal PD-1/PD-L1 Expression Predicts Outcome in Colon Cancer Patients.

Wyss J, Dislich B, Koelzer VH, Galván JA, Dawson H, Hädrich M, Inderbitzin D, Lugli A, Zlobec I, Berger MD.

Clin Colorectal Cancer. 2019 Mar;18(1):e20-e38. doi: 10.1016/j.clcc.2018.09.007. Epub 2018 Sep 21.

PMID:
30389315
13.

Tumour budding is associated with the mesenchymal colon cancer subtype and RAS/RAF mutations: a study of 1320 colorectal cancers with Consensus Molecular Subgroup (CMS) data.

Trinh A, Lädrach C, Dawson HE, Ten Hoorn S, Kuppen PJK, Reimers MS, Koopman M, Punt CJA, Lugli A, Vermeulen L, Zlobec I.

Br J Cancer. 2018 Nov;119(10):1244-1251. doi: 10.1038/s41416-018-0230-7. Epub 2018 Nov 2.

14.

CDX2 in colorectal cancer is an independent prognostic factor and regulated by promoter methylation and histone deacetylation in tumors of the serrated pathway.

Graule J, Uth K, Fischer E, Centeno I, Galván JA, Eichmann M, Rau TT, Langer R, Dawson H, Nitsche U, Traeger P, Berger MD, Schnüriger B, Hädrich M, Studer P, Inderbitzin D, Lugli A, Tschan MP, Zlobec I.

Clin Epigenetics. 2018 Sep 26;10(1):120. doi: 10.1186/s13148-018-0548-2.

15.

Tumor Heterogeneity in Primary Colorectal Cancer and Corresponding Metastases. Does the Apple Fall Far From the Tree?

Blank A, Roberts DE 2nd, Dawson H, Zlobec I, Lugli A.

Front Med (Lausanne). 2018 Aug 31;5:234. doi: 10.3389/fmed.2018.00234. eCollection 2018. Review.

16.

Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype.

Zinnall U, Weyerer V, Compérat E, Camparo P, Gaisa NT, Knuechel-Clarke R, Perren A, Lugli A, Toma M, Baretton G, Kristiansen G, Wirtz RM, Cheng L, Wullich B, Stoehr R, Hartmann A, Bertz S.

Hum Pathol. 2018 Oct;80:55-64. doi: 10.1016/j.humpath.2018.05.022. Epub 2018 Jun 6.

17.

International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.

Pagès F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, Lugli A, Zlobec I, Rau TT, Berger MD, Nagtegaal ID, Vink-Börger E, Hartmann A, Geppert C, Kolwelter J, Merkel S, Grützmann R, Van den Eynde M, Jouret-Mourin A, Kartheuser A, Léonard D, Remue C, Wang JY, Bavi P, Roehrl MHA, Ohashi PS, Nguyen LT, Han S, MacGregor HL, Hafezi-Bakhtiari S, Wouters BG, Masucci GV, Andersson EK, Zavadova E, Vocka M, Spacek J, Petruzelka L, Konopasek B, Dundr P, Skalova H, Nemejcova K, Botti G, Tatangelo F, Delrio P, Ciliberto G, Maio M, Laghi L, Grizzi F, Fredriksen T, Buttard B, Angelova M, Vasaturo A, Maby P, Church SE, Angell HK, Lafontaine L, Bruni D, El Sissy C, Haicheur N, Kirilovsky A, Berger A, Lagorce C, Meyers JP, Paustian C, Feng Z, Ballesteros-Merino C, Dijkstra J, van de Water C, van Lent-van Vliet S, Knijn N, Mușină AM, Scripcariu DV, Popivanova B, Xu M, Fujita T, Hazama S, Suzuki N, Nagano H, Okuno K, Torigoe T, Sato N, Furuhata T, Takemasa I, Itoh K, Patel PS, Vora HH, Shah B, Patel JB, Rajvik KN, Pandya SJ, Shukla SN, Wang Y, Zhang G, Kawakami Y, Marincola FM, Ascierto PA, Sargent DJ, Fox BA, Galon J.

Lancet. 2018 May 26;391(10135):2128-2139. doi: 10.1016/S0140-6736(18)30789-X. Epub 2018 May 10.

PMID:
29754777
18.

Tumour budding in pancreatic cancer revisited: validation of the ITBCC scoring system.

Karamitopoulou E, Wartenberg M, Zlobec I, Cibin S, Worni M, Gloor B, Lugli A.

Histopathology. 2018 Jul;73(1):137-146. doi: 10.1111/his.13508. Epub 2018 Apr 17.

PMID:
29495092
19.

Tumour budding in colorectal cancer: molecular rationale for clinical translation.

Zlobec I, Lugli A.

Nat Rev Cancer. 2018 Apr;18(4):203-204. doi: 10.1038/nrc.2018.1. Epub 2018 Jan 29. No abstract available.

PMID:
29376521
20.

[Current standards of pathological and molecular diagnostics in colorectal cancer].

Dawson H, Lugli A.

Ther Umsch. 2018;75(10):615-621. doi: 10.1024/0040-5930/a001048. Review. German.

PMID:
31232659
21.

Tumor-associated macrophages and response to 5-fluorouracil adjuvant therapy in stage III colorectal cancer.

Malesci A, Bianchi P, Celesti G, Basso G, Marchesi F, Grizzi F, Di Caro G, Cavalleri T, Rimassa L, Palmqvist R, Lugli A, Koelzer VH, Roncalli M, Mantovani A, Ogino S, Laghi L.

Oncoimmunology. 2017 Jul 12;6(12):e1342918. doi: 10.1080/2162402X.2017.1342918. eCollection 2017.

22.

Expression Patterns of TNFα, MAdCAM1, and STAT3 in Intestinal and Skin Manifestations of Inflammatory Bowel Disease.

Vavricka SR, Galván JA, Dawson H, Soltermann A, Biedermann L, Scharl M, Schoepfer AM, Rogler G, Prinz Vavricka MB, Terracciano L, Navarini A, Zlobec I, Lugli A, Greuter T.

J Crohns Colitis. 2018 Feb 28;12(3):347-354. doi: 10.1093/ecco-jcc/jjx158.

23.

TREM-1 promotes intestinal tumorigenesis.

Saurer L, Zysset D, Rihs S, Mager L, Gusberti M, Simillion C, Lugli A, Zlobec I, Krebs P, Mueller C.

Sci Rep. 2017 Nov 1;7(1):14870. doi: 10.1038/s41598-017-14516-4.

24.

World-Wide Immunoscore Task Force: meeting report from the "Melanoma Bridge", Napoli, November 30th-December 3rd, 2016.

Galon J, Lugli A, Bifulco C, Pages F, Masucci G, Marincola FM, Ascierto PA.

J Transl Med. 2017 Oct 20;15(1):212. doi: 10.1186/s12967-017-1310-9.

25.

The hyaluronan-mediated motility receptor RHAMM promotes growth, invasiveness and dissemination of colorectal cancer.

Mele V, Sokol L, Kölzer VH, Pfaff D, Muraro MG, Keller I, Stefan Z, Centeno I, Terracciano LM, Dawson H, Zlobec I, Iezzi G, Lugli A.

Oncotarget. 2017 Aug 3;8(41):70617-70629. doi: 10.18632/oncotarget.19904. eCollection 2017 Sep 19.

26.

[Lean management in the pathology laboratory].

Blank A, Dawson H, Hammer C, Perren A, Lugli A.

Pathologe. 2017 Nov;38(6):540-544. doi: 10.1007/s00292-017-0388-4. German. No abstract available.

PMID:
29043447
27.

Tumor Budding beim kolorektalen Karzinom: Ein morphologischer Biomarker für die Praxis.

Dawson H, Lugli A.

Ther Umsch. 2017 Sep;74(4):151-155. doi: 10.1024/0040-5930/a000898. Review. German. No abstract available.

PMID:
28950770
28.

Cytokeratin-based assessment of tumour budding in colorectal cancer: analysis in stage II patients and prospective diagnostic experience.

Koelzer VH, Assarzadegan N, Dawson H, Mitrovic B, Grin A, Messenger DE, Kirsch R, Riddell RH, Lugli A, Zlobec I.

J Pathol Clin Res. 2017 Jul 26;3(3):171-178. doi: 10.1002/cjp2.73. eCollection 2017 Jul.

29.

Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016.

Lugli A, Kirsch R, Ajioka Y, Bosman F, Cathomas G, Dawson H, El Zimaity H, Fléjou JF, Hansen TP, Hartmann A, Kakar S, Langner C, Nagtegaal I, Puppa G, Riddell R, Ristimäki A, Sheahan K, Smyrk T, Sugihara K, Terris B, Ueno H, Vieth M, Zlobec I, Quirke P.

Mod Pathol. 2017 Sep;30(9):1299-1311. doi: 10.1038/modpathol.2017.46. Epub 2017 May 26. Review.

30.

Digital analysis and epigenetic regulation of the signature of rejection in colorectal cancer.

Koelzer VH, Sokol L, Zahnd S, Christe L, Dawson H, Berger MD, Inderbitzin D, Zlobec I, Lugli A.

Oncoimmunology. 2017 Feb 6;6(4):e1288330. doi: 10.1080/2162402X.2017.1288330. eCollection 2017.

31.

[The pathology of adverse events with immune checkpoint inhibitors].

Koelzer VH, Glatz K, Bubendorf L, Weber A, Gaspert A, Cathomas G, Lugli A, Zippelius A, Kempf W, Mertz KD.

Pathologe. 2017 May;38(3):197-208. doi: 10.1007/s00292-017-0281-1. Review. German.

PMID:
28421272
32.

Correction: DAPK loss in colon cancer tumor buds: implications for migration capacity of disseminating tumor cells.

Ivanovska J, Zlobec I, Forster S, Karamitopoulou E, Dawson H, Koelzer VH, Agaimy A, Garreis F, Söder S, Laqua W, Lugli A, Hartmann A, Rau TT, Schneider-Stock R.

Oncotarget. 2017 Mar 14;8(11):18615-18616. doi: 10.18632/oncotarget.16154. No abstract available.

33.

Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.

Domingo E, Freeman-Mills L, Rayner E, Glaire M, Briggs S, Vermeulen L, Fessler E, Medema JP, Boot A, Morreau H, van Wezel T, Liefers GJ, Lothe RA, Danielsen SA, Sveen A, Nesbakken A, Zlobec I, Lugli A, Koelzer VH, Berger MD, Castellví-Bel S, Muñoz J; Epicolon consortium, de Bruyn M, Nijman HW, Novelli M, Lawson K, Oukrif D, Frangou E, Dutton P, Tejpar S, Delorenzi M, Kerr R, Kerr D, Tomlinson I, Church DN.

Lancet Gastroenterol Hepatol. 2016 Nov;1(3):207-216. doi: 10.1016/S2468-1253(16)30014-0. Epub 2016 Jul 20.

PMID:
28404093
34.

Timing of surgical antimicrobial prophylaxis: a phase 3 randomised controlled trial.

Weber WP, Mujagic E, Zwahlen M, Bundi M, Hoffmann H, Soysal SD, Kraljević M, Delko T, von Strauss M, Iselin L, Da Silva RXS, Zeindler J, Rosenthal R, Misteli H, Kindler C, Müller P, Saccilotto R, Lugli AK, Kaufmann M, Gürke L, von Holzen U, Oertli D, Bucheli-Laffer E, Landin J, Widmer AF, Fux CA, Marti WR.

Lancet Infect Dis. 2017 Jun;17(6):605-614. doi: 10.1016/S1473-3099(17)30176-7. Epub 2017 Apr 3. Erratum in: Lancet Infect Dis. 2017 Dec;17 (12 ):1232.

PMID:
28385346
35.

Construction and analysis of tissue microarrays in the era of digital pathology: a pilot study targeting CDX1 and CDX2 in a colon cancer cohort of 612 patients.

Nolte S, Zlobec I, Lugli A, Hohenberger W, Croner R, Merkel S, Hartmann A, Geppert CI, Rau TT.

J Pathol Clin Res. 2017 Jan 13;3(1):58-70. doi: 10.1002/cjp2.62. eCollection 2017 Jan.

36.

DNA profiling of tumor buds in colorectal cancer indicates that they have the same mutation profile as the tumor from which they derive.

Centeno I, Paasinen Sohns A, Flury M, Galván JA, Zahnd S, Koelzer VH, Sokol L, Dawson HE, Lugli A, Cathomas G, Zlobec I.

Virchows Arch. 2017 Mar;470(3):341-346. doi: 10.1007/s00428-017-2071-9. Epub 2017 Jan 27. No abstract available.

PMID:
28130698
37.

Comprehensive assessment of tumour budding by cytokeratin staining in colorectal cancer.

Rieger G, Koelzer VH, Dawson HE, Berger MD, Hädrich M, Inderbitzin D, Lugli A, Zlobec I.

Histopathology. 2017 Jun;70(7):1044-1051. doi: 10.1111/his.13164. Epub 2017 Mar 2.

38.

Macroscopy predicts tumor progression in gastric cancer: A retrospective patho-historical analysis based on Napoleon Bonaparte's autopsy report.

Dawson H, Novotny A, Becker K, Reim D, Langer R, Gullo I, Svrcek M, Niess JH, Tutuian R, Truninger K, Diamantis I, Blank A, Zlobec I, Riddell RH, Carneiro F, Fléjou JF, Genta RM, Lugli A.

Dig Liver Dis. 2016 Nov;48(11):1378-1385. doi: 10.1016/j.dld.2016.07.013. Epub 2016 Jul 21.

PMID:
27522550
39.

Systematic review and meta-analysis of the impact of tumour budding in colorectal cancer.

Rogers AC, Winter DC, Heeney A, Gibbons D, Lugli A, Puppa G, Sheahan K.

Br J Cancer. 2016 Sep 27;115(7):831-40. doi: 10.1038/bjc.2016.274. Epub 2016 Sep 6. Review.

40.

Inflammatory response in serrated precursor lesions of the colon classified according to WHO entities, clinical parameters and phenotype-genotype correlation.

Rau TT, Atreya R, Aust D, Baretton G, Eck M, Erlenbach-Wünsch K, Hartmann A, Lugli A, Stöhr R, Vieth M, Wirsing AM, Zlobec I, Katzenberger T.

J Pathol Clin Res. 2016 Feb 25;2(2):113-24. doi: 10.1002/cjp2.41. eCollection 2016 Apr.

41.

PTEN alterations of the stromal cells characterise an aggressive subpopulation of pancreatic cancer with enhanced metastatic potential.

Wartenberg M, Centeno I, Haemmig S, Vassella E, Zlobec I, Galván JA, Neuenschwander M, Schlup C, Gloor B, Lugli A, Perren A, Karamitopoulou E.

Eur J Cancer. 2016 Sep;65:80-90. doi: 10.1016/j.ejca.2016.06.013. Epub 2016 Jul 29.

PMID:
27475963
42.

Phenotyping of tumor-associated macrophages in colorectal cancer: Impact on single cell invasion (tumor budding) and clinicopathological outcome.

Koelzer VH, Canonica K, Dawson H, Sokol L, Karamitopoulou-Diamantis E, Lugli A, Zlobec I.

Oncoimmunology. 2015 Nov 9;5(4):e1106677. eCollection 2016 Apr.

43.

Predominant expression of truncated EpCAM is associated with a more aggressive phenotype and predicts poor overall survival in colorectal cancer.

Seeber A, Untergasser G, Spizzo G, Terracciano L, Lugli A, Kasal A, Kocher F, Steiner N, Mazzoleni G, Gastl G, Fong D.

Int J Cancer. 2016 Aug 1;139(3):657-63. doi: 10.1002/ijc.30099. Epub 2016 Apr 15.

44.

Impact of peritumoral and intratumoral budding in esophageal adenocarcinomas.

Thies S, Guldener L, Slotta-Huspenina J, Zlobec I, Koelzer VH, Lugli A, Kröll D, Seiler CA, Feith M, Langer R.

Hum Pathol. 2016 Jun;52:1-8. doi: 10.1016/j.humpath.2016.01.016. Epub 2016 Feb 10.

PMID:
26980046
45.

The IL-33/ST2 pathway contributes to intestinal tumorigenesis in humans and mice.

Mertz KD, Mager LF, Wasmer MH, Thiesler T, Koelzer VH, Ruzzante G, Joller S, Murdoch JR, Brümmendorf T, Genitsch V, Lugli A, Cathomas G, Moch H, Weber A, Zlobec I, Junt T, Krebs P.

Oncoimmunology. 2015 Jun 26;5(1):e1062966. eCollection 2016.

46.

Dual role of tumour-infiltrating T helper 17 cells in human colorectal cancer.

Amicarella F, Muraro MG, Hirt C, Cremonesi E, Padovan E, Mele V, Governa V, Han J, Huber X, Droeser RA, Zuber M, Adamina M, Bolli M, Rosso R, Lugli A, Zlobec I, Terracciano L, Tornillo L, Zajac P, Eppenberger-Castori S, Trapani F, Oertli D, Iezzi G.

Gut. 2017 Apr;66(4):692-704. doi: 10.1136/gutjnl-2015-310016. Epub 2015 Dec 30.

47.

VE1 immunohistochemistry predicts BRAF V600E mutation status and clinical outcome in colorectal cancer.

Schafroth C, Galván JA, Centeno I, Koelzer VH, Dawson HE, Sokol L, Rieger G, Berger MD, Hädrich M, Rosenberg R, Nitsche U, Schnüriger B, Langer R, Inderbitzin D, Lugli A, Zlobec I.

Oncotarget. 2015 Dec 8;6(39):41453-63. doi: 10.18632/oncotarget.6162.

48.

Tumor budding in colorectal cancer--ready for diagnostic practice?

Koelzer VH, Zlobec I, Lugli A.

Hum Pathol. 2016 Jan;47(1):4-19. doi: 10.1016/j.humpath.2015.08.007. Epub 2015 Sep 3. Review.

PMID:
26476568
49.

DAPK loss in colon cancer tumor buds: implications for migration capacity of disseminating tumor cells.

Ivanovska J, Zlobec I, Forster S, Karamitopoulou E, Dawson H, Koelzer VH, Agaimy A, Garreis F, Söder S, Laqua W, Lugli A, Hartmann A, Rau TT, Schneider-Stock R.

Oncotarget. 2015 Nov 3;6(34):36774-88. doi: 10.18632/oncotarget.4908. Erratum in: Oncotarget. 2017 Mar 14;8(11):18615-18616.

50.

Expression of the hyaluronan-mediated motility receptor RHAMM in tumor budding cells identifies aggressive colorectal cancers.

Koelzer VH, Huber B, Mele V, Iezzi G, Trippel M, Karamitopoulou E, Zlobec I, Lugli A.

Hum Pathol. 2015 Nov;46(11):1573-81. doi: 10.1016/j.humpath.2015.07.010. Epub 2015 Jul 29.

PMID:
26351067

Supplemental Content

Support Center